ARA-290 (cibinetide) is an investigational peptide derived from erythropoietin that has been studied for its interaction with tissue-protective pathways, including inflammatory signaling, nerve biology, and cellular repair. An intriguing compound for researchers exploring cytoprotection and regenerative mechanisms. For research purposes only.
ARA-290 (cibinetide) is an investigational peptide derived from erythropoietin that has been studied for its interaction with tissue-protective pathways, including inflammatory signaling, nerve biology, and cellular repair. An intriguing compound for researchers exploring cytoprotection and regenerative mechanisms. For research purposes only.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
on orders over $200
plain and unbranded packaging
256-bit SSL
Not a researcher? Exit
